Orgenesis Announces Collaboration with Immugenyx to Develop and Commercialize Advanced Hematopoietic Chimeras
Saturday, October 20, 2018
Orgenesis Inc., a manufacturer, service provider and developer of advanced cell therapies, today announced it has entered into a collaboration agreement with Immugenyx, LLC (“Immugenyx”), a wholly owned subsidiary of Hemogenyx Pharmaceuticals Plc.
Immugenyx will collaborate with Orgenesis to further the development and commercialization of its advanced hematopoietic chimeras (AHC). AHC, a new type of humanized mouse with a functional human immune system, is being developed by Immugenyx as an in vivo platform for disease modelling, drug and cell therapy development.
According to the terms of the agreement, Orgenesis shall receive the worldwide rights to market the products and shall serve as a global distributor of Immugenyx’s products. Immugenyx will retain exclusive rights to manufacture, make and supply to Orgenesis or its affiliates all the Immugenyx technology and/or licensed products that are marketed, sold or otherwise commercialized by Orgenesis.
In consideration for the license, Orgenesis and/or its affiliates will advance to Immugenyx a convertible loan in an amount of no less than $1.0 million for advancing the development of humanized mice models and related antibody development. Orgenesis shall also pay a royalty of 12% of Orgenesis’ net revenues resulting from the sale or licensing of products involving the use of Immugenyx’ AHC technology.
Vered Caplan, Chief Executive Officer, stated, “We are excited to collaborate with Immugenyx, as we believe that this technology has broad potential to accelerate drug development across a wide range of indications, by mimicking the human immune system within a mouse model. Through this novel platform, our goal is to advance the field of cell therapy through a unique and innovative way of testing the human immune system.”
Vladislav Sandler, Co-Founder and CEO of HemoGenyx and its subsidiary, Immugenyx, LLC, commented, “Orgenesis is an ideal partner, as a global leader in the field of cell therapy. Moreover, Orgenesis has built a global platform with broad capabilities ranging from therapeutic development to manufacturing, licensing, regulatory and commercialization.”
